ReNew Q2 FY27 slides: revenue up 28%, guidance raised on manufacturing

ReNew reported Q2 FY2027 revenue of INR 49.6 billion, up 28% year over year, and adjusted EBITDA of INR 33.6 billion, also up 28%; profit after tax rose 37% to INR 6.4 billion. After first-half adjusted EBITDA reached INR 64 billion, up 20%, management raised the lower end of FY2027 adjusted EBITDA guidance to INR 105 billion from INR 103 billion, while keeping the upper end at INR 109 billion. Manufacturing generated INR 4.1 billion of quarterly adjusted EBITDA, though management cautioned that margins may moderate as Indian industry capacity expands. The company also updated investors on its proposed $7.02-per-share cash take-private transaction, expected to become effective in Q1 2027 subject to approvals and other conditions.

Analysis

The signed take-private offer, not the operating beat, is the near-term equity anchor: at the cited share price, the cash consideration implies only about 2% gross upside before closing, while public holders give up most participation in the raised guidance and manufacturing upside. That spread is compensation for a multi-month, conditional process—not evidence the shares are cheap. The vote commitments reduce one execution hurdle, but approval conditions and the scheme timetable still matter; the article gives no financing-condition detail or credible break price, so downside asymmetry cannot be quantified from these facts alone.

Over 1–3 months, manufacturing is the most likely source of estimate revisions, but investors should discount the annualized run-rate claims: cell capacity additions across India may compress pricing and margins just as ReNew brings on new capacity. External orders provide some visibility, not proof of sustained returns on expansion capital. Over 6–18 months, vertical integration could protect captive-project economics, yet the ingot-wafer build adds funding and execution exposure to a company whose operating-project leverage remains elevated. Improving collections and capital recycling help, but aged Andhra Pradesh receivables and asset-sale proceeds should not be treated as recurring cash generation.

Contrarian point: strong demand and operating results may look bullish, but they do not automatically accrue to minority shareholders if the transaction closes. Conversely, if it fails, the stock must again clear a leveraged, capital-intensive growth story without the cash-offer floor. The article’s optimism on data-center demand is a long-dated opportunity, not near-term contracted earnings evidence.

Key Decisions for Investors

• Treat RNW primarily as a deal-arbitrage position, not a growth-equity long. Before entering, verify the scheme conditions, regulatory approvals, financing provisions, expected closing timetable, and the share price around announcement to estimate failure downside; the stated spread alone does not establish attractive risk/reward.
• For existing holders, compare the remaining cash-offer spread with the loss implied by a failed deal and the opportunity cost of capital. Avoid adding solely on the guidance increase; reduce or exit if the spread widens on a material approval delay or adverse transaction amendment.
• Track the next 1–2 quarters for manufacturing segment EBITDA versus guidance, cell utilization and realized pricing as industry capacity arrives, and external order-book conversion. Margin deterioration or a guidance cut would falsify the view that manufacturing can sustain current contribution.
• Monitor operating-project leverage, cash flow to equity, asset-sale closings, and aged receivables separately. A slowdown in recycling proceeds or renewed collection delays would weaken the deleveraging thesis; no standalone short or competitor pair is justified without clearer post-deal exposure and valuation data.